Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer

作者：Bharali Dhruba J; Sudha Thangirala; Cui Huadong; Mian Badar M; Mousa Shaker A^*

来源：Nanomedicine: Nanotechnology, Biology and Medicine , 2017, 13(1): 263-273.

DOI：10.1016/j.nano.2016.08.017

• Anti-CD24
• Docetaxel
• PLGA nanoparticle
• Prostate cancer
• Targeted therapy

Nanoparticle (NP)-mediated, noninvasively targeted and image-guided therapies have potential to improve efficacy and safety of cancer therapeutics. We report synthesis and use of poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) NPs for targeted delivery of docetaxel. We synthesized docetaxel encapsulated NPs conjugated to anti-CD24 (for targeting) and/or an optical probe (for tracking) and evaluated efficacy in a prostate cancer mouse model. We observed preferential accumulation of anti-CD24 conjugated NPs (encapsulating docetaxel) compared to the non-conjugated NPs 24 hours after a single injection into luciferase-expressing PC3M prostate cancer tumor. In the same mouse model, we found significant (P < 0.01) accumulation of docetaxel (similar to 10-fold higher) in tumor after treatment with PLGA-PEG NPs encapsulating docetaxel and conjugated to anti-CD24 compared to non-conjugated NPs. Enhanced accumulation was associated with reduced tumor mass and tumor viability. These data support the potential impact of nano-targeted delivery of chemotherapy in enhancing the differential tumor delivery and anticancer efficacy in prostate cancer.

• 出版日期2017-1